Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment

ConclusionsThe exposure levels of janagliflozin in T2DM patients were slightly increased with worsening of RI (i.e., 11% increase in the AUC in patients with moderate RI compared with the normal renal function group). Despite worsening of renal function, janagliflozin exerted a significant pharmacologic effect and was well tolerated, even in patients with moderate RI, implying a promising role in the treatment of patients with in T2DM.Registration China Drug Trial register (http://www.chinadrugtrials.org.cn/I) identifier no.: CTR20192721.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research